European Journal of Cancer - McMaster Experts

publication venue for

The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma 2020
Viral sensitizers potential infection of cancer cells via NF-kappaB 2019
Expression of monoamine oxidase a is correlated with three-dimensional tumorsphere-formation by human breast tumor cells lines 2018
A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226) 2016
Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221 2016
Tumour matrix stiffness regulates metastasis by promoting cancer cell interactions with the endothelium 2016
2200 TOPGEAR: A randomized phase M/MI trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. Interim results from an international, intergroup trial of the AGITG/TROG/NCIC CTG/EORTC 2015
2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma 2015
3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses 2015
3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC) 2015
205 Metformin to modulate AMP-kinase and enhance chemotherapy and radiotherapy in non-small cell lung cancer 2014
508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041) 2014
A cost-minimization analysis of NCIC Clinical Trials Group LY.12: A phase III study of gemcitabine, clexamethasone, and cisplatin (GDP) compared to dexamethasone, cytarabine, and cisplatin (DHAP) for patients with relapsed or refractory aggressive histology non-Hodgkin's lymphoma 2013
Difficulties in meeting accrual and obtaining adequate follow up in palliative trials: Results from an intergroup randomized trial of single vs multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20 2013
Genomic testing in cancer (GTC): Patient knowledge, attitudes and expectations 2013
Homecare utilization and costs in stage IV lung cancer: a Canadian public payer experience 2013
Prognostic risk stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy 2013
Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial 2013
607 NCIC CTG IND.196: Phase I Study of Foretinib (GSK1363089) and Erlotinib in Patients with Advanced Pretreated NSCLC 2012
239 The Cancer-associated K351N Mutation Affects the Ubiquitination and the Translocation to Mitochondria of p53 Protein 2012
Fulvestrant Alone or with Concomitant Anastrozole Vs Exemestane Following Progression On Non-steroidal Aromatase Inhibitor - First Results of the SoFEa Trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747) 2012
Impact of Survivorship Care Plans (SCP) On Adherence to Guidelines, Health Service Measures, and Patient-reported Outcomes (PRO): Extended Results of a Multicenter Randomized Clinical Trial (RCT) with Breast Cancer Survivors 2012
1314 POSTER Quality of Reporting of Modern Randomized Controlled Trials in Oncology 2011
3001 POSTER DISCUSSION Ultra-low-molecular-weight Heparin (ULMWH) Semuloparin for Prevention of Venous Thromboembolism (VTE) in Cancer Patients Receiving Chemotherapy: Consistent Beneficial Effect Across Cancer Stage and Location Subgroups 2011
406 INVITED Stereotactic Radiotherapy for Liver Metastases 2011
6088 POSTER KRAS and EGFR MicroRNAs Regulation and Cetuximab/Panitumumab Sensitivity in Metastatic Colorectal Cancer Patients 2011
Quality of Life in the ICON7 GCIG Phase III Randomised Clinical Trial 2011
Introduction 2006
Final results of a phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumours 2002
Phase II study of OSI-774 in patients with metastatic colorectal cancer 2002
The NCIC CTG MA.14 experience with the gallbladder toxicity of octreotide pamoate (oncolar) in a postmenopausal patient population undergoing adjuvant treatment for stage 1-3 breast cancer 2002
Assessment of alternative and complimentary medicines and devices in cancer patients attending a multi-disciplinary cancer centre 1999
NCIC CTG IND 113: two phase I dose escalation pharmacokinetic (PK) studies of BAY 12-9566 (BAY) in combination with either doxorubicin (DOX) or modulated 5-fluorouracil (FU) 1999
Results of a randomized phase II study of two schedules of bryostatin-I in patients with malignant melanoma: experience with the multivariate stopping rule 1999
p53 and WAF1 expression in epithelial ovarian cancer: Prognostic and predictive implications 1998
S35 CEF versus CMF in premenopausal women — Recent update 1998
Economic evaluation of chemotherapy with Mitoxantrone plus Prednisone for symptomatic hormone resistant prostate cancer based on a Canadian randomised trial with palliative endpoints 1997
Opportunities to reduce the cost of care for breast cancer (BC) in Canada 1997
Phase II trial of the multi-targeted antifolate LY231514 (MTA) as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) 1997
Concurrent daily chemotherapy with hyperfractionated thoracic irradiation in stage IIIA&B NSCLC 1995
Preventing nausea and vomiting during days 2-7 following high dose cisplatin chemotherapy (HDCP) 1995
The health economics of lung cancer and an estimate of the cost effectiveness of single agent gemcitabine in stage IV NSCLC 1995
A model for the study of treatment response in human normal and tumour cells 1987
117 (PB-117) Poster Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective. 200:113693. 2024
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. 180:108-116. 2023
Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4. 175:236-245. 2022
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. 171:124-132. 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. 163:55-65. 2022
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. 160:1-11. 2022
Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update. 154:92-101. 2021
Health care utilisation and costs associated with different treatment protocols for newly diagnosed childhood acute lymphoblastic leukaemia: A population-based study in Ontario, Canada. 151:126-135. 2021
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. 142:132-140. 2021
Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer. 138:S12-S13. 2020
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. 135:203-210. 2020
Current state of quality of life and patient-reported outcomes research. 121:55-63. 2019
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. 108:69-77. 2019
Patient-reported symptoms after breast cancer diagnosis and treatment: A retrospective cohort study. 101:1-11. 2018
C-statistic: A brief explanation of its construction, interpretation and limitations. 90:130-132. 2018
Corrigendum to “Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles” [Eur J Cancer 70 (2017) 62–74]. 83:335-335. 2017
Exercise training improves physical function and fitness in long-term paediatric brain tumour survivors treated with cranial irradiation. 80:63-72. 2017
Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6). 72:192-199. 2017
Nuclear transportation of exogenous epidermal growth factor receptor and androgen receptor via extracellular vesicles. 70:62-74. 2017
Serotonergic antagonists target breast tumor-initiating cells in mouse models of human breast cancer. 69:S83-S83. 2016
Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. 59:65-78. 2016
Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. 51:2501-2507. 2015
1525 Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV): Efficacy and safety over multiple cycles of highly or moderately emetogenic chemotherapy. 51:S212-S213. 2015
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. 51:1405-1414. 2015
Influence of censoring on conclusions of trials for women with metastatic breast cancer. 51:721-724. 2015
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. 50:706-712. 2014
Clear cell renal cell carcinoma induces fibroblast-mediated production of stromal periostin. 49:3537-3546. 2013
Symptom clusters in a population-based ambulatory cancer cohort validated using bootstrap methods. 48:3073-3081. 2012
357 Impact of Survivorship Care Plans (SCP) On Adherence to Guidelines, Health Service Measures, and Patient-reported Outcomes (PRO): Extended Results of a Multicenter Randomized Clinical Trial (RCT) with Breast Cancer Survivors. 48:S147-S147. 2012
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. 48:324-332. 2012
Central nervous system atypical teratoid rhabdoid tumours: The Canadian Paediatric Brain Tumour Consortium experience. 48:353-359. 2012
Nutritional status at diagnosis is related to clinical outcomes in children and adolescents with cancer: A perspective from Central America. 48:243-252. 2012
Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: A phase II trial. 48:37-45. 2012
Early stopping rules in oncology: Considerations for clinicians. 47:2381-2386. 2011
6604 POSTER Updated Survival and Genomic Analysis of a Phase II Trial of Temsirolimus in Advanced Neuroendocrine Carcinomas. 47:S473-S473. 2011
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. 47:1373-1379. 2011
Randomised controlled trials in oncology closed early for benefit: Trends in methodology, results, and interpretation. 47:854-863. 2011
The unclear zone in phase II clinical trials. 46:2408-2413. 2010
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. 46:1573-1579. 2010
Health-related quality of life of long-term childhood cancer survivors: A population-based study from the Childhood Cancer Registry of Piedmont, Italy. 43:2545-2552. 2007
Long term survivors of childhood cancer: Cure and care. 43:1778-1780. 2007
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. 43:660-675. 2007
Osteonecrosis in children and adolescents with cancer – An adverse effect of systemic therapy. 43:683-689. 2007
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. 42:1875-1880. 2006
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?. 42:548-556. 2006
Use of paediatric versus adult oncology treatment centres by adolescents 15–19 years old: the Canadian Childhood Cancer Surveillance and Control Program. 41:404-410. 2005
Economic evaluation of treatments for cancer in childhood. 40:1335-1345. 2004
Canada's Population Health Model (POHEM). 37:1797-1804. 2001
The adolescent with cancer. 37:1523-1527. 2001
A randomized trial of high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell support (asct) compared to standard chemo therapy (ct) in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) clinical trials group study. 37:S285-S285. 2001
Health-related quality of life of patients with malignant pleural mesothelioma treated with pemetrexed disodium. 37:s282. 2001
NCIC CTG IND.122: a phase I/II pharmacokinetics (PK) and pharmacodynamic (PD) study of zd1839 (iressa ‘TM’). Final phase I results and preliminary phase II results of ZD1839 (750 mg/day) in patients (pts) with colorectal cancer. 37:S289-S289. 2001
Physical interaction with yes-associated protein enhances p73 transcriptional activity. 37:S279-S279. 2001
Randomised phase II study of BMS-275291 versus placebo in patients (pts) with stage IIIb or IV non small cell lung cancer (NSCLC) receiving paclitaxel + carboplatin (PC): National Cancer Institute of Canada clinical trials group (NCIC CTG) br.18. 37:S19-S20. 2001
The p53 family: What implications in human carcinogenesis?. 37:S138-S139. 2001
Zometa® is effective and well tolerated in the prevention of skeletal related events secondary to metastatic breast cancer treated with hormonal therapy. 37:S152-S152. 2001
IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. 37:478-485. 2001
Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer. 36:2329-2334. 2000
Response from D. Feeny, et al.. 36:1460-1461. 2000
Estimates of the lifetime costs of breast cancer treatment in Canada. 36:724-735. 2000
NCIC CTG IND102: a phase II study of the oral platinum compound BMS-182751 in patients with advanced and or recurrent squamous cell carcinoma of the cervix. 35:S235-S235. 1999
Æ-941, an inhibitor of angiogenesis: rationale for development in combination with induction chemotherapy/radiotherapy in patients with non-small-cell lung cancer (nsclc). 35:S250-S250. 1999
Applicability of the Health Utilities Index to a Population of Childhood Survivors of Central Nervous System Tumours in the U.K.. 35:256-261. 1999
Health-related quality of life in survivors of tumours of the central nervous system in childhood—a preference-based approach to measurement in a cross-sectional study1Presented in part to the meetings of the International Society of Pediatric Oncology (SIOP) in Paris, September 1994 and Montevideo, October 1995.1. 35:248-255. 1999
Detection of SYT–SSX1/2 fusion transcripts by reverse transcriptase–polymerase chain reaction (RT–PCR) is a valuable diagnostic tool in synovial sarcoma. 34:2087-2093. 1998
The prognostic role of gender in survival of adult cancer patients. 34:2271-2278. 1998
The prognostic role of gender in survival of adult cancer patients. EUROCARE Working Group.. 34:2271-2278. 1998
Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop. 34:1317-1333. 1998
A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer. 34:1008-1014. 1998
Osteopenia in children surviving brain tumours. 34:873-877. 1998
The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma. 34:31-36. 1998
PP15. Methods for conducting economic analysis of the long-term management of breast cancer: Description of two current Canadian studies. 33:S19-S20. 1997
Phase II trial of the multi-targeted antifolate LY231514 (MTA) as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC). 33:S231-S231. 1997
Direct osteolysis induced by metastatic murine melanoma cells: Role of matrix metalloproteinases. 33:918-925. 1997
A survey of telomerase activity in human cancer. 33:787-791. 1997
Letter to the Editor: Comments on Health-related Quality of Life of Adults Surviving Malignancies in Childhood, Apajasalo et al., Eur J Cancer, 32A, No. 8, pp. 1354-1358, 1996. 33:506-507. 1997
The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. 32:2249-2255. 1996
1057 The health economics of lung cancer and an estimate of the cost effectiveness of single agent gemcitabine in stage IV NSCLC. 31:S221-S221. 1995
1100 Concurrent daily chemotherapy with hyperfractionated thoracic irradiation in stage IIIA & B NSCLC. 31:S229-S229. 1995
1204 Preventing nausea and vomiting during days 2–7 following high dose cisplatin chemotherapy (HDCP). 31:S251-S251. 1995
VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer. 30:299-303. 1994
A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. 29:37-43. 1993
Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer. 29:21-23. 1993
Dexamethasone (DEX) improves the efficacy of granisetron (GRAN) in the first 24 hours following high dose cisplatin (HDCP) chemotherapy. 29:S208-S208. 1993
Clinical significance of natural killer cell cytotoxicity: Need for proper data analysis in the design of clinical studies. 21:1287-1293. 1985

European Journal of Cancer Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)